0001209191-21-052077.txt : 20210817
0001209191-21-052077.hdr.sgml : 20210817
20210817193443
ACCESSION NUMBER: 0001209191-21-052077
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210813
FILED AS OF DATE: 20210817
DATE AS OF CHANGE: 20210817
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Clague Laura
CENTRAL INDEX KEY: 0001388773
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 211184614
MAIL ADDRESS:
STREET 1: 370 PARK RANCH PLACE
CITY: ESCONDIDO
STATE: CA
ZIP: 92025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Travere Therapeutics, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262383102
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 888-969-7879
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Retrophin, Inc.
DATE OF NAME CHANGE: 20130220
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-13
0
0001438533
Travere Therapeutics, Inc.
TVTX
0001388773
Clague Laura
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DR., SUITE 300
SAN DIEGO
CA
92130
0
1
0
0
Chief Financial Officer
Common Stock
2021-08-13
4
A
0
4500
0.00
A
32723
D
Common Stock
2021-08-17
4
S
0
1407
17.1182
D
31316
D
On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On August 13, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the PROTECT study.
Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
/s/ Elizabeth E. Reed, Attorney-in-Fact
2021-08-17